{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:47:42Z","timestamp":1792784862657,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Koch Institute MIT School of Science Fellowship in Cancer Research"},{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Rapid development of antisense therapies can enable on-demand responses to new viral pathogens and make personalized medicine for genetic diseases practical. Antisense phosphorodiamidate morpholino oligomers (PMOs) are promising candidates to fill such a role, but their challenging synthesis limits their widespread application. To rapidly prototype potential PMO drug candidates, we report a fully automated flow-based oligonucleotide synthesizer. Our optimized synthesis platform reduces coupling times by up to 22-fold compared to previously reported methods. We demonstrate the power of our automated technology with the synthesis of milligram quantities of three candidate therapeutic PMO sequences for an unserved class of Duchenne muscular dystrophy (DMD). To further test our platform, we synthesize a PMO that targets the genomic mRNA of SARS-CoV-2 and demonstrate its antiviral effects. This platform could find broad application not only in designing new SARS-CoV-2 and DMD antisense therapeutics, but also for rapid development of PMO candidates to treat new and emerging diseases.<\/jats:p>","DOI":"10.1038\/s41467-021-24598-4","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T06:26:57Z","timestamp":1626762417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers"],"prefix":"10.1038","volume":"12","author":[{"given":"Chengxi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle A.","family":"Totaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Mijalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kruttika-Suhas","family":"Phadke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0875-6390","authenticated-orcid":false,"given":"Nina","family":"Hartrampf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly K.","family":"Schissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar J.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Loas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7747-8983","authenticated-orcid":false,"given":"Nicola L. B.","family":"Pohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7242-801X","authenticated-orcid":false,"given":"Bradley L.","family":"Pentelute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"24598_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41594-018-0054-4","volume":"25","author":"J Lieberman","year":"2018","unstructured":"Lieberman, J. Tapping the RNA world for therapeutics. Nat. Struct. Mol. Biol. 25, 357\u2013364 (2018).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"24598_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1089\/ard.1991.1.191","volume":"1","author":"JS Cohen","year":"1991","unstructured":"Cohen, J. S. Informational drugs: a new concept in pharmacology. Antisense Res. Dev. 1, 191\u2013193 (1991).","journal-title":"Antisense Res. Dev."},{"key":"24598_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1146\/annurev-pharmtox-010818-021050","volume":"59","author":"CIE Smith","year":"2019","unstructured":"Smith, C. I. E. & Zain, R. Therapeutic oligonucleotides: state of the art. Annu. Rev. Pharmacool. Toxicol. 59, 605\u2013630 (2019).","journal-title":"Annu. Rev. Pharmacool. Toxicol."},{"key":"24598_CR4","doi-asserted-by":"publisher","unstructured":"Jackson L. A. et al. An mRNA vaccine against SARS-CoV-2 \u2014 preliminary report. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2022483 (2020).","DOI":"10.1056\/NEJMoa2022483"},{"key":"24598_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396, 467\u2013478 (2020).","journal-title":"Lancet"},{"key":"24598_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan, M. J. et al. Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589\u2013593 (2020).","journal-title":"Nature"},{"key":"24598_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","volume":"35","author":"A Khvorova","year":"2017","unstructured":"Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238\u2013248 (2017).","journal-title":"Nat. Biotechnol."},{"key":"24598_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","volume":"7","author":"J Summerton","year":"1997","unstructured":"Summerton, J. & Weller, D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7, 187\u2013195 (1997).","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"24598_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1089\/oli.1.1996.6.267","volume":"6","author":"RM Hudziak","year":"1996","unstructured":"Hudziak, R. M. et al. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 6, 267\u2013272 (1996).","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"24598_CR10","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/jps.10088","volume":"91","author":"V Arora","year":"2002","unstructured":"Arora, V., Knapp, D. C., Reddy, M. T., Weller, D. D. & Iversen, P. L. Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J. Pharm. Sci. 91, 1009\u20131018 (2002).","journal-title":"J. Pharm. Sci."},{"key":"24598_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.virol.2005.08.034","volume":"344","author":"KL Holden","year":"2006","unstructured":"Holden, K. L. et al. Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3\u2032 stem-loop structure. Virology 344, 439\u2013452 (2006).","journal-title":"Virology"},{"key":"24598_CR12","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.3390\/v4112806","volume":"4","author":"PL Iversen","year":"2012","unstructured":"Iversen, P. L. et al. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses 4, 2806\u20132830 (2012).","journal-title":"Viruses"},{"key":"24598_CR13","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1128\/AAC.00644-06","volume":"50","author":"Q Ge","year":"2006","unstructured":"Ge, Q. et al. Inhibition of multiple subtypes of influenza a virus in cell cultures with morpholino oligomers. Antimicrob. Agents Chemother. 50, 3724\u20133733 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"24598_CR14","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1128\/AAC.00069-07","volume":"51","author":"TS Deas","year":"2007","unstructured":"Deas, T. S. et al. In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus. Antimicrob. Agents Chemother. 51, 2470 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"24598_CR15","doi-asserted-by":"publisher","first-page":"9665","DOI":"10.1128\/JVI.79.15.9665-9676.2005","volume":"79","author":"BW Neuman","year":"2005","unstructured":"Neuman, B. W. et al. Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers. J. Virol. 79, 9665\u20139676 (2005).","journal-title":"J. Virol."},{"key":"24598_CR16","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1128\/JVI.02360-06","volume":"81","author":"R Burrer","year":"2007","unstructured":"Burrer, R. et al. Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models. J. Virol. 81, 5637\u20135648 (2007).","journal-title":"J. Virol."},{"key":"24598_CR17","unstructured":"Fox, C. M. J. & Weller, D. D. Method of synthesis of morpholino oligomers. US patent 8,299,206 B2 (2008)."},{"key":"24598_CR18","unstructured":"Summerton, J. E. & Weller, D. D. Uncharged morpholino-based polymers having phosphorous containing chiral intersubunit linkages. US patent 5,185,444 (1991)."},{"key":"24598_CR19","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.bmcl.2011.12.021","volume":"22","author":"T Harakawa","year":"2012","unstructured":"Harakawa, T., Tsunoda, H., Ohkubo, A., Seio, K. & Sekine, M. Development of an efficient method for phosphorodiamidate bond formation by using inorganic salts. Bioorg. Med. Chem. Lett. 22, 1445\u20131447 (2012).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"24598_CR20","doi-asserted-by":"publisher","first-page":"4.65.1","DOI":"10.1002\/0471142700.nc0465s62","volume":"62","author":"J Bhadra","year":"2015","unstructured":"Bhadra, J., Pattanayak, S. & Sinha, S. Synthesis of morpholino monomers, chlorophosphoramidate monomers, and solid-phase synthesis of short morpholino oligomers. Curr. Protoc. Nucleic Acid Chem. 62, 4.65.1\u20134.65.26 (2015).","journal-title":"Curr. Protoc. Nucleic Acid Chem."},{"key":"24598_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10989-006-9059-7","volume":"13","author":"M Schn\u00f6lzer","year":"2007","unstructured":"Schn\u00f6lzer, M., Alewood, P., Jones, A., Alewood, D. & Kent, S. B. H. In situ neutralization in boc-chemistry solid phase peptide synthesis. Int. J. Pept. Res. Ther. 13, 31\u201344 (2007).","journal-title":"Int. J. Pept. Res. Ther."},{"key":"24598_CR22","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1126\/science.1057324","volume":"291","author":"OJ Plante","year":"2001","unstructured":"Plante, O. J., Palmacci, E. R. & Seeberger, P. H. Automated solid-phase synthesis of oligosaccharides. Science 291, 1523\u20131527 (2001).","journal-title":"Science"},{"key":"24598_CR23","doi-asserted-by":"publisher","first-page":"9896","DOI":"10.1039\/C3CC44709J","volume":"49","author":"J-i Yoshida","year":"2013","unstructured":"Yoshida, J.-i, Takahashi, Y. & Nagaki, A. Flash chemistry: flow chemistry that cannot be done in batch. Chem. Commun. 49, 9896\u20139904 (2013).","journal-title":"Chem. Commun."},{"key":"24598_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","volume":"80","author":"YA Heo","year":"2020","unstructured":"Heo, Y. A. Golodirsen: first approval. Drugs 80, 329\u2013333 (2020).","journal-title":"Drugs"},{"key":"24598_CR25","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","volume":"76","author":"YY Syed","year":"2016","unstructured":"Syed, Y. Y. Eteplirsen: first global approval. Drugs 76, 1699\u20131704 (2016).","journal-title":"Drugs"},{"key":"24598_CR26","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S. Viltolarsen: first approval. Drugs 80, 1027\u20131031 (2020).","journal-title":"Drugs"},{"key":"24598_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","volume":"30","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus, A. et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum. Mutat. 30, 293\u2013299 (2009).","journal-title":"Hum. Mutat."},{"key":"24598_CR28","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nrg1180","volume":"4","author":"JC van Deutekom","year":"2003","unstructured":"van Deutekom, J. C. & van Ommen, G. J. Advances in Duchenne muscular dystrophy gene therapy. Nat. Rev. Genet. 4, 774\u2013783 (2003).","journal-title":"Nat. Rev. Genet."},{"key":"24598_CR29","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nchembio.2318","volume":"13","author":"AJ Mijalis","year":"2017","unstructured":"Mijalis, A. J. et al. A fully automated flow-based approach for accelerated peptide synthesis. Nat. Chem. Biol. 13, 464 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"24598_CR30","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1126\/science.abb2491","volume":"368","author":"N Hartrampf","year":"2020","unstructured":"Hartrampf, N. et al. Synthesis of proteins by automated flow chemistry. Science 368, 980\u2013987 (2020).","journal-title":"Science"},{"key":"24598_CR31","doi-asserted-by":"publisher","unstructured":"Lee, B., Mijalis, A. J., Ozturk, M. & Pohl, N. L. Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers. a-callahan\/MechWolf_Pull 0.1.1. https:\/\/doi.org\/10.5281\/zenodo.3774509 (2020).","DOI":"10.5281\/zenodo.3774509"},{"key":"24598_CR32","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.1002\/anie.201801167","volume":"57","author":"JM Wolfe","year":"2018","unstructured":"Wolfe, J. M. et al. Perfluoroaryl bicyclic cell-penetrating peptides for delivery of antisense oligonucleotides. Angew. Chem. Int. Ed. 57, 4756\u20134759 (2018).","journal-title":"Angew. Chem. Int. Ed."},{"key":"24598_CR33","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1093\/nar\/29.19.3965","volume":"29","author":"P Sazani","year":"2001","unstructured":"Sazani, P. et al. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res. 29, 3965\u20133974 (2001).","journal-title":"Nucleic Acids Res."},{"key":"24598_CR34","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/hmg\/10.15.1547","volume":"10","author":"JCT van Deutekom","year":"2001","unstructured":"van Deutekom, J. C. T. et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum. Mol. Genet. 10, 1547\u20131554 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"24598_CR35","unstructured":"Sazani, P. & Kole, R. Multiple exon skipping compositions for DMD. US patent 9,434,948 B2 (2015)."},{"key":"24598_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/jac\/dkaa460","volume":"76","author":"K Rosenke","year":"2021","unstructured":"Rosenke, K. et al. Inhibition of SARS-CoV-2 in vero cell cultures by peptide-conjugated morpholino oligomers. J. Antimicrob. Chemother. 76, 413\u2013417 (2021).","journal-title":"J. Antimicrob. Chemother."},{"key":"24598_CR37","doi-asserted-by":"publisher","first-page":"eaav4580","DOI":"10.1126\/sciadv.aav4580","volume":"5","author":"S Xia","year":"2019","unstructured":"Xia, S. et al. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci. Adv. 5, eaav4580 (2019).","journal-title":"Sci. Adv."},{"key":"24598_CR38","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","volume":"30","author":"S Xia","year":"2020","unstructured":"Xia, S. et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 30, 343\u2013355 (2020).","journal-title":"Cell Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24598-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24598-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24598-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T08:40:06Z","timestamp":1669970406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24598-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["24598"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-24598-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv.12685886.v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"assertion":[{"value":"17 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.L.P. is a co-founder of Amide Technologies and Resolute Bio. Both companies focus on the development of protein and peptide therapeutics. An international patent application covering part of this work has been filed by MIT and Sarepta Therapeutics (Int. Pat. Appl. WO2019060862A1). M.Z. and H.Z. are employees of Sarepta Therapeutics. K.A.T. is an employee of Amide Technologies. The authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4396"}}